Acasă › Cancer de sân › California › Mountain View
Studii clinice pentru Cancer de sân în Mountain View, CA
26 studii pentru Cancer de sân caută participanți în și în jurul orașului Mountain View (în aproximativ 50 km). Deschideți un studiu pentru a vedea criteriile de eligibilitate și cum să contactați echipa de cercetare.
Text oficial al studiului (în engleză)
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
În curs de recrutareFaza 3
- Stanford Women's Cancer Center, Palo Alto · La 5 mi distanță
A Study of PHST001 in Advanced Solid Tumors
În curs de recrutareFaza 1
- Stanford University School of Medicine, Palo Alto · La 5 mi distanță
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
În curs de recrutareFaza 3
- El Camino Hospital, Mountain View
- Palo Alto Medical Foundation, Mountain View
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
În curs de recrutareFaza 1/2
- Stanford Medicine Cancer Center, Stanford · La 5 mi distanță
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
În curs de recrutareFaza 3
- El Camino Hospital Cancer Center ( Site 0096), Mountain View
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
În curs de recrutareFaza 1
- Stanford University Medical Center, Stanford · La 5 mi distanță
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
În curs de recrutareFaza 1
- Stanford University Medical Center, Stanford · La 5 mi distanță
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
În curs de recrutareFaza 3
- Stanford Cancer Center, Palo Alto · La 5 mi distanță
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
În curs de recrutareFaza 3
- Stanford University School of Medicine - Stanford Cancer Institute (SCI) - Stanford Women's Cancer Center, Palo Alto · La 5 mi distanță
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
În curs de recrutareFaza 3
- Stanford Women's Cancer Center, Palo Alto · La 5 mi distanță
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
În curs de recrutareFaza 1
- Stanford University Hospital, Stanford · La 5 mi distanță
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
În curs de recrutareFaza 3
- Research Site, Palo Alto · La 5 mi distanță
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
În curs de recrutareFaza 2
- Stanford Cancer Institute, Palo Alto · La 5 mi distanță
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
În curs de recrutareFaza 3
- Palo Alto Medical Foundation Research Center, Palo Alto · La 5 mi distanță
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
În curs de recrutareFaza 3
- Palo Alto Medical Foundation-Camino Division, Mountain View
- Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View
- Palo Alto Medical Foundation Health Care, Palo Alto · La 5 mi distanță
- și încă 1
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
În curs de recrutareFaza 2
- Stanford University, Stanford · La 5 mi distanță
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
În curs de recrutareFaza 2/3
- Local Institution - 0358, Stanford · La 5 mi distanță
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
În curs de recrutareFaza 3
- Stanford Medicine Cancer Center - Stanford Women's Cancer Center, Palo Alto · La 5 mi distanță
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
În curs de recrutareFaza 1
- Stanford University Medical Center, Palo Alto · La 5 mi distanță
Magnetic Resonance Imaging of Breast Cancer
În curs de recrutareVoluntari sănătoși bineveniți
- Stanford University School of Medicine, Stanford · La 5 mi distanță
Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples
În curs de recrutareStudiu observațional
- Stanford University School of Medicine, Stanford · La 5 mi distanță
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
În curs de recrutareFaza 3
- Palo Alto Medical Foundation-Camino Division, Mountain View
- Palo Alto Medical Foundation Health Care, Palo Alto · La 5 mi distanță
- Stanford Cancer Institute Palo Alto, Palo Alto · La 5 mi distanță
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
În curs de recrutareFaza 1
- Stanford Cancer Institute, Stanford · La 5 mi distanță
Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma
În curs de recrutare
- Stanford University, Stanford · La 5 mi distanță
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
În curs de recrutareStudiu observațional
- Stanford Cancer Institute, Palo Alto · La 5 mi distanță
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
În curs de recrutareStudiu observațional
- Massive Bio SYNERGY-AI site, Stanford · La 5 mi distanță
Studii pentru Cancer de sân în alte orașe
- New York City, NY136 studii
- Houston, TX126 studii
- Boston, MA112 studii
- Nashville, TN81 studii
- Los Angeles, CA73 studii
- Edison, NJ68 studii
- St. Louis, MO64 studii
- Queens, NY64 studii
- Durham, NC64 studii
- Chicago, IL59 studii
- Philadelphia, PA56 studii
- Dallas, TX55 studii
Alte studii în Mountain View
- Cancer (toate tipurile)40 studii
- Cancer metastatic25 studii
- Cancer pulmonar cu celule non-pătrate21 studii
- Leucemie mieloasă acută19 studii
- Cancer ovarian19 studii
- Tulburare din spectrul autist17 studii
- Cancer pulmonar17 studii
- Cancer de prostată15 studii
- Insuficiență cardiacă15 studii
- Autism13 studii
- Leucemie limfoblastică acută13 studii
- Cancer colorectal13 studii
Sursă: ClinicalTrials.gov, date preluate la 6 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.